Gyre Therapeutics, Inc. (GYRE)
(Delayed Data from NSDQ)
$15.06 USD
-0.18 (-1.18%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.90 -0.16 (-1.06%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GYRE 15.06 -0.18(-1.18%)
Will GYRE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for GYRE
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
Gyre announces publication in Journal of Gastroenterology and Hepatology
Week In Review: MediLink And BioNTech Form $1.8B ADC Partnership
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership